United States Genomics in Cancer Care Market to Hit $21.86 Billion by 2033, Driven by Cancer Diagnostics, Targeted Therapies & Biotech Investments

Leander, Texas, United States - Nov.19.2025
As per DataM intelligence research report"The global genomics in cancer care market size reached US$ 16.14billion with rise of US$18.6billion in 2024 is expected to reach US$ 72.87billion by 2033, growing at a CAGR of 16.8%during the forecast period 2025-2033.". Integration of genomics into cancer care is revolutionizing treatment strategies and enabling personalized medicine.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/genomics-in-cancer-care-market?sp

United States: Recent Industry Developments

✅ In November 2025, Foundation Medicine launched expanded genomic profiling solutions for oncology, enabling comprehensive mutation and biomarker analysis. The platform supports personalized treatment planning and clinical trial matching. This development strengthens Foundation Medicine's leadership in precision cancer care.

✅ In October 2025, Tempus introduced AI-integrated genomic testing for cancer patients, combining DNA and RNA analysis for actionable insights. The solutions accelerate treatment decisions and improve outcomes. This reinforces Tempus' position in U.S. precision oncology.

✅ In September 2025, Guardant Health expanded liquid biopsy genomic tests for non-invasive cancer monitoring, detecting mutations and treatment resistance. The approach supports early intervention and therapy optimization. This positions Guardant Health as a key innovator in cancer genomics.

✅ In August 2025, Caris Life Sciences launched next-generation sequencing panels for solid tumors, integrating multi-omic data for comprehensive cancer care. The technology enhances precision medicine adoption. This strengthens Caris Life Sciences' presence in U.S. oncology genomics.

Japan: Recent Industry Developments

✅ In November 2025, Fujirebio introduced expanded cancer genomic testing services for early detection and targeted therapy guidance. The solutions combine DNA profiling and biomarker analysis. This development reinforces Fujirebio's leadership in Japan's precision oncology sector.

✅ In October 2025, Sysmex Corporation launched genomic platforms for cancer diagnostics, integrating AI-based interpretation to guide treatment decisions. The technology improves accuracy and patient outcomes. This positions Sysmex as a leader in Japan's cancer genomics market.

✅ In September 2025, Takara Bio expanded cancer gene panels for clinical applications, enabling comprehensive mutation detection and therapy selection. The solutions support personalized oncology strategies. This strengthens Takara Bio's role in Japan's genomic cancer care.

✅ In August 2025, SRL, Inc. introduced multi-gene sequencing platforms for tumor profiling and liquid biopsy analysis, enhancing early detection and monitoring. The approach improves clinical decision-making and patient management. This reinforces SRL's presence in Japan's cancer genomics landscape.

Genomics in Cancer Care Market: Drivers

The genomics in cancer care market is witnessing rapid growth as precision medicine becomes central to oncology diagnosis, treatment, and management. Genomic technologies enable comprehensive analysis of tumor DNA and RNA to identify mutations, biomarkers, and therapeutic targets, allowing for personalized treatment strategies. Rising prevalence of cancer, increasing awareness of targeted therapies, and demand for early detection and accurate prognosis are driving adoption in hospitals, research institutions, and diagnostic laboratories. Technological advancements in next-generation sequencing, bioinformatics, and liquid biopsy are enhancing the speed, accuracy, and accessibility of genomic testing in oncology. Additionally, supportive regulatory frameworks and growing investment in cancer genomics research are further accelerating market expansion.

Integration of genomics with immunotherapy, targeted therapy, and pharmacogenomics is improving patient outcomes and minimizing adverse effects, paving the way for individualized cancer care. Collaborations between biotech firms, pharmaceutical companies, and healthcare providers are fostering innovation and development of comprehensive genomic panels and companion diagnostics. Increasing patient awareness and healthcare professional education on precision oncology are boosting adoption of genomic-guided treatment plans. Expansion of digital health platforms and AI-driven analytics is enhancing interpretation of complex genomic data for clinical decision-making. With advancements in technology and a strong focus on personalized, effective cancer care, the genomics in cancer care market is poised for significant global growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/genomics-in-cancer-care-market?sp

Genomics in Cancer Care Market: Major Players

Illumina, Thermos Fisher Scientific, BGI Genomics, QIAGEN, Roche Diagnostics, Guardant Health, Natera, Myriad Genetics and among others.

Segment Covered in the Genomics in Cancer Care Market:

By Product Type
Instruments lead with 55% share, driven by high adoption of sequencing platforms, PCR systems, and automated analysis tools in cancer diagnostics and research. Their role in tumor profiling and biomarker detection continues to expand. Consumables hold 45%, supported by recurring demand for reagents, kits, chips, and sample prep supplies. Increasing test volumes across hospitals and labs drives strong growth in this segment.

By Technology
Next-generation sequencing dominates with 48% share, driven by its ability to deliver comprehensive tumor genomic profiles and identify complex mutations. PCR follows with 28%, widely used for rapid mutation screening and minimal residual disease detection. Microarrays hold 12%, supporting expression profiling and targeted assays. Nucleic acid extraction & purification and other technologies collectively account for 12%, enabling upstream sample preparation and specialized workflows.

By Application
Diagnostics leads with 52% share, fueled by rising demand for early cancer detection, tumor mutation analysis, and companion diagnostics. Personalized medicine represents 31%, driven by targeted therapy selection, treatment monitoring, and pharmacogenomic insights. Drug discovery and development hold 17%, with genomics supporting biomarker discovery, clinical trial stratification, and oncology research. All segments benefit from expanding precision oncology adoption.

By End User
Hospitals and oncology clinics dominate with 38% share, supported by rapid integration of genomic testing into routine cancer care. Diagnostic labs hold 32%, driven by high test volumes and specialized sequencing capabilities. Academic and research centers account for 19%, focusing on cancer genomics, biomarker research, and translational studies. Pharma companies and CROs represent 11%, leveraging genomics for oncology pipeline development and targeted drug programs.

Regional Analysis

North America - 39% Share
North America leads with 39%, driven by advanced cancer genomic testing, strong reimbursement systems, and leadership in precision medicine programs. The U.S. dominates with high adoption of NGS-based oncology panels, liquid biopsies, and companion diagnostics. Research investments and clinical trial networks further strengthen the market.

Europe - 29% Share
Europe holds 29%, supported by national genomic initiatives, strong oncology infrastructure, and integration of molecular testing into clinical guidelines. The U.K., Germany, and France drive adoption across hospitals and research centers. Growing emphasis on early cancer detection and personalized therapies boosts demand.

Asia Pacific - 26% Share
Asia Pacific accounts for 26%, fueled by expanding healthcare investment, rising cancer prevalence, and growing adoption of genomic testing in China, Japan, India, and South Korea. Government-funded precision medicine programs accelerate growth. Affordable genomic platforms improve accessibility across emerging markets.

South America - 3% Share
South America holds 3%, with Brazil and Argentina leading adoption of oncology genomic tests. Growth is supported by expanding private healthcare networks and increasing demand for personalized cancer therapies. Limited public funding slows full-scale adoption but awareness and accessibility continue improving.

Middle East & Africa - 3% Share
The Middle East & Africa capture 3%, driven by rising investments in cancer centers, genomic labs, and precision oncology programs in GCC nations. Africa is gradually adopting genomics for early detection and inherited cancer risk assessment. Infrastructure improvements support modest but steady growth.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=genomics-in-cancer-care-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.